Clinical Trial Update: Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) [Phase 3]

View source ↗

Summary

Phase 3, single-arm trial evaluating valoctocogene roxaparvovec for Hemophilia A has completed, with results posted on 2023-11-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Roctavian (valoctocogene roxaparvovec)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2023-11-28